Related references
Note: Only part of the references are listed.Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Imran G. House et al.
CLINICAL CANCER RESEARCH (2020)
CXCL-10: a new candidate for melanoma therapy?
Hossein Bagheri et al.
CELLULAR ONCOLOGY (2020)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model
Harried Mirzaei et al.
CANCER LETTERS (2018)
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Patrick Danaher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman et al.
CELL (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors
Zinal S. Chheda et al.
JOURNAL OF IMMUNOLOGY (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints
M. E. Mikucki et al.
NATURE COMMUNICATIONS (2015)
Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
Mark Ayers et al.
Journal for ImmunoTherapy of Cancer (2015)
Heparanase enhances myeloma progression via CXCL10 downregulation
U. Barash et al.
LEUKEMIA (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
RNAscope A Novel in Situ RNA Analysis Platform for Formalin-Fixed, Paraffin-Embedded Tissues
Fay Wang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2012)
CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo
F. Antonicelli et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts
AL Feldman et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Improved survival in tumor-bearing SCID mice treated with interferon-γ-inducible protein 10 (IP-10/CXCL10)
DA Arenberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)
Share Paper
